Literature DB >> 1777376

The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol.

H L Elliott1, P A Meredith, C McNally, J L Reid.   

Abstract

1. The interactions between the dihydropyridine calcium antagonist nisoldipine and two beta-adrenoceptor blocker drugs (atenolol and propranolol) were investigated in two groups of healthy normotensive subjects. 2. The steady state plasma concentrations of both beta-adrenoceptor blockers were significantly altered by the addition of nisoldipine: for propranolol there were significant increases in Cmax, by about 50%, and in AUC by about 30% and for atenolol there was a significant increase in Cmax, by about 20%. 3. The addition of nisoldipine was also associated with significant changes in apparent liver blood flow (measured by indocyanine green clearance) from 1.4 to 2.4 l min-1 in the atenolol group and from 1.3 to 2.3 l min-1 in the propranolol group. 4. Both nisoldipine-beta-adrenoceptor blocker combinations were associated with small enhanced blood pressure reductions e.g. from 104/60 with atenolol alone to 98/50 mm Hg with the combination but there was no alteration to the extent of beta-adrenoceptor blockade (as assessed by bicycle ergometry). 5. This pharmacodynamic profile in healthy normotensives is consistent with the known therapeutic efficacy of such combination treatments in patients with hypertension and angina. 6. It is suggested that there is a pharmacokinetic component to the efficacy of this type of combination, perhaps reflecting vasodilator-induced changes in drug absorption and/or hepatic extraction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777376      PMCID: PMC1368535          DOI: 10.1111/j.1365-2125.1991.tb03916.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Nicardipine does not influence the pharmacokinetics and pharmacodynamics of atenolol.

Authors:  I Vercruysse; D F Schoors; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

2.  The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow.

Authors:  P A Meredith; F Pasanisi; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

3.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

4.  Acute effects of nisoldipine, propranolol, and their combination in patients with chronic stable angina: a double-blind, randomized, cross-over, placebo-controlled study.

Authors:  L De Caprio; M Papa; D Acanfora; P Abete; F Gallucci; F Covelluzzi; A M Cicatiello; F Rengo
Journal:  J Cardiovasc Pharmacol       Date:  1990-08       Impact factor: 3.105

5.  Atenolol determination by high-performance liquid chromatography and fluorescence detection.

Authors:  Y G Yee; P Rubin; T F Blaschke
Journal:  J Chromatogr       Date:  1979-04-01

6.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

Authors:  D Gangji; M Juvent; G Niset; M Wathieu; M Degreve; R Bellens; J Poortmans; S Degre; T J Fitzsimons; A Herchuelz
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

7.  Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects.

Authors:  J Feely
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  The combination of propranolol and nifedipine in the treatment of hypertension: acute and long term effects.

Authors:  Y Yagil; B Leibel; I Kobrin; J Stessman; D B Ishay
Journal:  Postgrad Med J       Date:  1983       Impact factor: 2.401

9.  Antianginal efficiency of nifedipine with and without a beta-blocker, studied with exercise test. A double-blind, randomized subacute study.

Authors:  L G Ekelund; L Orö
Journal:  Clin Cardiol       Date:  1979-06       Impact factor: 2.882

10.  Nifedipine and propranolol: a beneficial drug interaction.

Authors:  H J Dargie; P G Lynch; D M Krikler; L Harris; S Krikler
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

View more
  9 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

3.  The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin.

Authors:  R Donnelly; H L Elliott; P A Meredith; C A Howie; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.

Authors:  H D Langtry; C M Spencer
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 5.  Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

6.  Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.

Authors:  I Vercruysse; D F Schoors; D L Massart; A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

7.  Efficacy and Tolerability of Nisoldipine Coat-Core vs Diltiazem Retard in Combination with a Beta-Blocker in Patients with Stable Exertional Angina Pectoris.

Authors:  A Melcher; J Abelin; O Luurila
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 8.  Nimodipine. Potential for drug-drug interactions in the elderly.

Authors:  W Mück; G Ahr; J Kuhlmann
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 9.  Clinical pharmacokinetics of nisoldipine coat-core.

Authors:  R Heinig
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.